Mineralys Therapeutics (MLYS) Aktienübersicht
Mineralys Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das in den Vereinigten Staaten Medikamente gegen Krankheiten entwickelt, die durch dysreguliertes Aldosteron verursacht werden. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
MLYS Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mineralys Therapeutics, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$27.98 |
| 52-Wochen-Hoch | US$47.65 |
| 52-Wochen-Tief | US$22.30 |
| Beta | 0.67 |
| 1 Monat Veränderung | 5.15% |
| 3 Monate Veränderung | 13.60% |
| 1 Jahr Veränderung | -29.82% |
| 3 Jahre Veränderung | 161.01% |
| 5 Jahre Veränderung | n/a |
| Veränderung seit IPO | 51.74% |
Aktuelle Nachrichten und Updates
MLYS: Late Stage NDA Progress Is Expected To Unlock Upside Potential
Analysts have trimmed their fair value estimate for Mineralys Therapeutics to $48.50 from $50.88, reflecting updated assumptions around lorundrostat's long term sales ramp and a slightly higher discount rate following recent Street research and the revised $49 price target cited by BofA in August 2026. What’s in the News for Mineralys Therapeutics Mineralys Therapeutics reported second quarter 2026 results that included a net loss, which has kept attention on the company’s cash needs and development spending.Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Summary Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with Baxfendy, MLYS's focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction. MLYS's $661M in cash and a new CMO with deep cardiovascular experience support its high-risk, high-reward profile in a massive addressable market. Read the full article on Seeking Alpha
MLYS: December PDUFA Decision Will Define Upside For Hypertension Franchise
Analysts have trimmed their fair value estimate for Mineralys Therapeutics to about $31.65 from roughly $33.82, citing updated assumptions for lorundrostat that factor in a slower long term sales ramp than previously modeled and the implications of AstraZeneca's earlier Baxfendy launch and label clarity on Mineralys' positioning and potential partnerships. Analyst Commentary Recent Street research on Mineralys Therapeutics highlights a mix of optimism around lorundrostat's opportunity and growing caution on execution risk, especially now that AstraZeneca's Baxfendy has clarity on label, pricing, and payer access.Recent updates
MLYS: Late Stage NDA Progress Is Expected To Unlock Upside Potential
Analysts have trimmed their fair value estimate for Mineralys Therapeutics to $48.50 from $50.88, reflecting updated assumptions around lorundrostat's long term sales ramp and a slightly higher discount rate following recent Street research and the revised $49 price target cited by BofA in August 2026. What’s in the News for Mineralys Therapeutics Mineralys Therapeutics reported second quarter 2026 results that included a net loss, which has kept attention on the company’s cash needs and development spending.Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision
Summary Mineralys Therapeutics, Inc. is upgraded to Buy, with lorundrostat poised for FDA approval in December and a strong commercial launch anticipated. Despite AstraZeneca's first-mover advantage with Baxfendy, MLYS's focused strategy and robust funding position it to capture significant hypertension market share. Lorundrostat demonstrates competitive efficacy and safety, with potential for blockbuster revenues and future label expansion beyond blood pressure reduction. MLYS's $661M in cash and a new CMO with deep cardiovascular experience support its high-risk, high-reward profile in a massive addressable market. Read the full article on Seeking AlphaMLYS: December PDUFA Decision Will Define Upside For Hypertension Franchise
Analysts have trimmed their fair value estimate for Mineralys Therapeutics to about $31.65 from roughly $33.82, citing updated assumptions for lorundrostat that factor in a slower long term sales ramp than previously modeled and the implications of AstraZeneca's earlier Baxfendy launch and label clarity on Mineralys' positioning and potential partnerships. Analyst Commentary Recent Street research on Mineralys Therapeutics highlights a mix of optimism around lorundrostat's opportunity and growing caution on execution risk, especially now that AstraZeneca's Baxfendy has clarity on label, pricing, and payer access.Regulatory And Competitive Pressures Will Challenge Hypertension Launch Yet Longer Term Potential Remains
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension and related comorbidities. What are the underlying business or industry changes driving this perspective?
Hypertension PDUFA Decision And Large Target Population Will Support Strong Long Term Opportunity
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor for patients with uncontrolled and resistant hypertension. What are the underlying business or industry changes driving this perspective?Hypertension And Cardiorenal Catalysts Will Reshape Long Term Prospects For This Biotech
Catalysts About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions. What are the underlying business or industry changes driving this perspective?Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Summary Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders. The Anti-Hypertensive drugs market worldwide is expected to reach $22.41 billion by 2025. Read the full article on Seeking AlphaIs Mineralys Therapeutics (NASDAQ:MLYS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
Summary I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company’s slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects. My main concern with MLYS is its relatively short cash runway. But still, I think it has enough runway to fund its key trials through 2025. Overall, I feel MLYS is a good speculative “Buy” at these levels, especially after a substantial pullback in the shares with promising catalysts lined up in 2025. Read the full article on Seeking AlphaHere's Why We're Not Too Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Mineralys In Hypertension: Upcoming Catalysts And Strong Positioning
Summary Mineralys' lorundrostat, a selective aldosterone synthase inhibitor, shows promise in treating resistant hypertension with fewer side effects compared to current MRAs. Upcoming catalysts include pivotal phase 2 and 3 trial results in 2025, with significant potential market impact if successful. Despite a solid cash position, further funding may be needed for regulatory stages, making acquisition by a major player a strategic move. Given its potential and current valuation, I recommend a cautious buy for Mineralys at these prices. Read the full article on Seeking AlphaAktionärsrenditen
| MLYS | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -4.5% | 1.2% | 0.5% |
| 1Y | -29.8% | 37.1% | 12.0% |
Rendite im Vergleich zur Industrie: MLYS unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 37.1% erzielte.
Rendite vs. Markt: MLYS hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 12 erzielte.
Preisvolatilität
| MLYS volatility | |
|---|---|
| MLYS Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: MLYS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: MLYSDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2019 | 76 | Jon Congleton | mineralystx.com |
Mineralys Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das in den Vereinigten Staaten Medikamente zur Behandlung von Krankheiten entwickelt, die durch dysreguliertes Aldosteron verursacht werden. Das Unternehmen entwickelt Lorundrostat, einen firmeneigenen, oral verabreichten, hochselektiven Aldosteron-Synthase-Hemmer für die Behandlung von kardiorenalen Erkrankungen, die von dysreguliertem Aldosteron betroffen sind, wie Bluthochdruck, chronische Nierenerkrankungen und obstruktive Schlafapnoe. Das Unternehmen war früher als Catalys SC1, Inc. bekannt und änderte im Mai 2020 seinen Namen in Mineralys Therapeutics, Inc. Mineralys Therapeutics, Inc. wurde im Jahr 2019 gegründet und hat seinen Hauptsitz in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.'s Grundlagenzusammenfassung
| MLYS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.43b |
| Gewinn(TTM) | -US$349.58m |
| Umsatz(TTM) | n/a |
Ist MLYS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MLYS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$0 |
| Kosten der Einnahmen | US$0 |
| Bruttogewinn | US$0 |
| Sonstige Ausgaben | US$349.58m |
| Gewinn | -US$349.58m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -3.95 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 17.7% |
Wie hat sich MLYS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/17 06:23 |
| Aktienkurs zum Tagesende | 2026/09/17 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Mineralys Therapeutics, Inc. wird von 9 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Umer Raffat | Evercore ISI |
| Richard J. Law | Goldman Sachs |